CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy Assisted Corneal Transplantation in the Treatment of Refractory Viral Keratitis
Latest Information Update: 26 Aug 2022
At a glance
- Drugs BD 111 (Primary)
- Indications Dendritic keratitis; Ocular herpes simplex
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai BDgene
- 20 Aug 2022 As per ClinicalTrials.gov, protocol amended as change in timeframe of primary end point from 24months to 12 months.
- 20 Aug 2022 Status changed from active, no longer recruiting to completed.
- 25 May 2021 Status changed from recruiting to active, no longer recruiting.